Chlorine in PDB 6fgb: Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab

The structure of Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab, PDB code: 6fgb was solved by K.Sarkar, T.Ceska, C.Meier, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	30.00 / 2.90
Space group	P 32 2 1
Cell size a, b, c (Å), α, β, γ (°)	150.100, 150.100, 89.150, 90.00, 90.00, 120.00
R / Rfree (%)	23.2 / 28.4

The structure of Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab also contains other interesting chemical elements:

Sodium

(Na)

2 atoms

The binding sites of Chlorine atom in the Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab (pdb code 6fgb). This binding sites where shown within 5.0 Angstroms radius around Chlorine atom.
In total 2 binding sites of Chlorine where determined in the Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab, PDB code: 6fgb:
Jump to Chlorine binding site number: 1; 2;

Chlorine binding site 1 out of 2 in the Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 1 of Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab within 5.0Å range: probe atom residue distance (Å) B Occ A:Cl401 b:68.2 occ:1.00 OD1 A:ASN55 3.2 49.3 1.0 O A:GLN56 3.7 50.1 1.0 CG A:ASN55 4.0 49.5 1.0 NH2 A:ARG169 4.1 57.1 1.0 C A:GLN56 4.2 49.9 1.0 ND2 A:ASN55 4.3 50.1 1.0 N A:GLN56 4.4 49.1 1.0 N A:VAL57 4.8 50.1 1.0 CA A:GLN56 4.9 49.9 1.0 C A:ASN55 4.9 48.5 1.0

Chlorine binding site 2 out of 2 in the Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 2 of Human Fcrn Extra-Cellular Domain Complexed with Fab Fragment of Rozanolixizumab within 5.0Å range: probe atom residue distance (Å) B Occ L:Cl301 b:67.8 occ:1.00 O L:ALA48 3.0 41.6 1.0 N L:LYS44 3.5 40.1 1.0 CB L:LYS47 3.7 44.2 1.0 CG L:LYS47 4.1 45.8 1.0 CB L:LYS44 4.1 39.9 1.0 CA L:GLN43 4.2 40.0 1.0 CG L:LYS44 4.2 39.0 1.0 C L:ALA48 4.2 41.9 1.0 CE1 L:PHE42 4.2 34.8 1.0 C L:GLN43 4.4 39.9 1.0 O L:PHE42 4.4 40.5 1.0 CA L:LYS44 4.4 40.2 1.0 CD1 L:PHE42 4.6 35.9 1.0 CD L:LYS44 4.6 39.1 1.0 N L:ALA48 4.7 42.8 1.0 O L:LYS44 4.8 40.7 1.0 C L:LYS47 4.8 43.4 1.0 CZ L:PHE42 4.8 34.7 1.0 CB L:LYS50 4.8 40.5 1.0 C L:PRO49 4.8 41.2 1.0 N L:GLN43 4.9 40.0 1.0 CG L:LYS50 4.9 40.0 1.0 CA L:LYS47 4.9 43.8 1.0 C L:PHE42 4.9 40.1 1.0 CA L:PRO49 5.0 41.2 1.0 N L:LYS50 5.0 41.0 1.0

B.Smith, A.Kiessling, R.Lledo-Garcia, K.L.Dixon, L.Christodoulou, M.C.Catley, P.Atherfold, L.E.D'hooghe, H.Finney, K.Greenslade, H.Hailu, L.Kevorkian, D.Lightwood, C.Meier, R.Munro, O.Qureshi, K.Sarkar, S.P.Shaw, R.Tewari, A.Turner, K.Tyson, S.West, S.Shaw, F.R.Brennan. Generation and Characterization of A High Affinity Anti-Human Fcrn Antibody, Rozanolixizumab, and the Effects of Different Molecular Formats on the Reduction of Plasma Igg Concentration. Mabs V. 10 1111 2018.
ISSN: ESSN 1942-0870
PubMed: 30130439
DOI: 10.1080/19420862.2018.1505464